Back to News
Market Impact: 0.22
Corcym Announces First-in-Human Implant of TriMemo®, Extending Its Memo Platform to Tricuspid Valve Repair
Source: Business Wire
Healthcare & BiotechProduct LaunchesTechnology & Innovation
Corcym announced the first human implant of TriMemo, its purpose-built adaptive tricuspid valve repair device incorporating superelastic Memo technology. The clinical milestone supports validation of the company's structural-heart product innovation, though the release provided no financial, regulatory, or commercial-sales details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Elon Musk’s dangerous grip on outer space
- J&J prostate cancer drug shows promising tumor responses in early trial
- Ukraine Says Restrictions on Starlink Speed Have Been Lifted
- AI agents could disrupt bank deposits. Why Wall Street may be overreacting
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI in Asset Management: 2026 Statistics That Hold Up
- What is Broker Research and RMS Systems (And How to Actually Use Them)